How to appeal an Aetna hemophilia & bleeding disorders denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for hemophilia & bleeding disorders

Cited policy: Aetna Clinical Policy Bulletin (Hemophilia)

Recognizes prophylaxis as standard for severe. CPB explicitly cites WFH + MASAC.

How Aetna denies hemophilia & bleeding disorders — and how to counter it

Where Aetna pushes back: 1) Hemlibra without prior factor failure; 2) Gene therapy 'experimental'; 3) Continuation requires inhibitor confirmation.

Counter-arguments that hold up: Quote CPB 0240 — itself recognizes Hemlibra for severe Hem A. HAVEN 1 / HAVEN 3 pivotal data. Roctavian FDA approval Jun 29, 2022 + GENEr8-1; Hemgenix FDA approval Nov 22, 2022 + HOPE-B — BLA approvals, NOT experimental.

What Aetna typically denies for hemophilia & bleeding disorders

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For hemophilia & bleeding disorders, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the hemophilia & bleeding disorders treatments most often flagged for prior auth, step therapy, or medical necessity review:

• SHL FVIII
• EHL FVIII
• Hemlibra
• Roctavian
• SHL FIX
• EHL FIX

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.